About

Vaxxas is a venture capital funded technology start-up company developing technology that originated from Professor Mark Kendall’s research group at the Australian Institute of Bioengineering & Nanotechnology at The University of Queensland, the Australian university where some of the groundbreaking immunological work on human papilloma vaccines was performed.

Company details

Websitewww.vaxxas.com/

Vaxxas is developing an advanced platform for needle-free vaccine delivery.

The Nanopatch™ is comprised of an ultra-high density array of very short projections – invisible to the naked eye – that are coated with vaccine. Application of the Nanopatch™ to the skin is designed to be pain free, rapidly delivering vaccine directly to the abundant populations of immune cells immediately below the skin surface.

In a range of studies in animal models, using as little as 1/10 of a normal dose of vaccine, the Nanopatch™ has been shown to produce an immune response equivalent to a full dose delivered by needle and syringe. Furthermore, a vaccine-coated Nanopatch™ can be stable at room temperature, avoiding cost and logistic impediments of cold-chain. Vaxxas has completed two clinical studies and a third study (influenza) is currently underway. The company has preclinical programs funded by WHO (polio) and the Bill and Melinda Gates Foundation (measles/rubella) in development.

Our offering

Vaxxas is a venture capital funded technology start-up company developing technology that originated from Professor Mark Kendall’s research group at the Australian Institute of Bioengineering & Nanotechnology at The University of Queensland, the Australian university where some of the groundbreaking immunological work on human papilloma vaccines was performed.

The initial investments into Vaxxas have been made by an international consortium of investors including One Ventures, Brandon Capital, Healthcare Ventures and Medical Research Commercialisation Fund. Leveraging both the potent immunogenic response and product thermostability of Nanopatch-enabled vaccines, Vaxxas is applying its technology to improve the performance of vaccines, with initial applications targeting infectious disease and oncology.

Vaxxas aims to partner with vaccine companies who are seeking a differentiated, high-performance, cost-effective and safe vaccine delivery platform. We anticipate applying our expertise in developing and optimizing the Nanopatch™ technology for each of our partners in their particular disease areas of interest so that they can take unique, valuable vaccine products to the market with access to the Nanopatch™ technology via a licensing arrangement.